CA2158933A1 - Methodes de suppression du rejet de greffes - Google Patents

Methodes de suppression du rejet de greffes

Info

Publication number
CA2158933A1
CA2158933A1 CA002158933A CA2158933A CA2158933A1 CA 2158933 A1 CA2158933 A1 CA 2158933A1 CA 002158933 A CA002158933 A CA 002158933A CA 2158933 A CA2158933 A CA 2158933A CA 2158933 A1 CA2158933 A1 CA 2158933A1
Authority
CA
Canada
Prior art keywords
cells
vector construct
recombinant vector
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002158933A
Other languages
English (en)
Inventor
John F. Warner
Carol-Gay Anderson
Douglas J. Jolly
Thomas W. Dubensky, Jr.
Carlos E. Ibanez
Michael J. Irwin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2158933A1 publication Critical patent/CA2158933A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des cellules tissulaires d'un animal qu'on a transformées avec une structure de vecteur de recombinaison qui (a) dirige l'expression d'une protéine ou d'une partie active de cette dernière; (b) transcrit un message non codant; ou (c) transcrit un ribozyme capable d'inhiber la présentation de l'antigène du complexe majeur d'histocompatibilité. Selon un autre aspect, les cellules sont transformées à l'aide de deux ou plusieurs de ces protéines, message non codant ou ribozymes, ou avec des combinaisons de ces derniers. Ces cellules tissulaires sont tout particulièrement utiles dans des procédés de suppression des rejets de greffes. Cette invention concerne également des compositions pharmaceutiques comprenant lesdites cellules tissulaires transformées.
CA002158933A 1993-09-03 1994-09-02 Methodes de suppression du rejet de greffes Abandoned CA2158933A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11682793A 1993-09-03 1993-09-03
US08/116,827 1993-09-03

Publications (1)

Publication Number Publication Date
CA2158933A1 true CA2158933A1 (fr) 1995-03-09

Family

ID=22369470

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002158933A Abandoned CA2158933A1 (fr) 1993-09-03 1994-09-02 Methodes de suppression du rejet de greffes

Country Status (5)

Country Link
EP (1) EP0716691A1 (fr)
JP (1) JPH09503656A (fr)
AU (1) AU7681394A (fr)
CA (1) CA2158933A1 (fr)
WO (1) WO1995006717A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6657996A (en) * 1995-07-18 1997-02-18 Guido Krupp Ribozymes for the selective inhibition of expression by mhc llele genes, and drugs containing such ribozymes
WO1998031813A1 (fr) * 1997-01-17 1998-07-23 Roche Diagnostics Gmbh Inhibiteur de la presentation d'antigenes par des molecules de mhc de classe i
US20030134809A1 (en) * 2001-12-17 2003-07-17 Isis Pharmaceuticals Inc. Antisense modulation of ABC transporter MHC 1 expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729251D0 (en) * 1987-12-15 1988-01-27 Cogent Ltd Human cytomegalovirus protein
WO1991018088A1 (fr) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Vecteurs eucaryotiques a base de virus adeno-associes (aav)
DE69131908T3 (de) * 1991-02-19 2008-04-03 Oxford Biomedica (Uk) Ltd. Viruspartikel mit veraendertem wirtspektrum
WO1993014769A1 (fr) * 1992-01-31 1993-08-05 The Regents Of The University Of California Procede de production de cellules donneuses universelles
CA2110946A1 (fr) * 1992-12-09 1994-06-10 Elazar Rabbani Methode pour rendre un element du corps immunocompatible au moyen d'un construit d'acide nucleique, construit d'acide nucleique servant a inhiber ou a reguler la fonction d'un gene de la reponse immunitaire et element immunocompatible contenant un construit d'acide nucleique servant a inhiber ou a reguler la fonction d'un gene de la reponse
AU5962694A (en) * 1992-12-31 1994-08-15 Exemplar Corporation Producing cells for transplantation to reduce host rejection and resulting cells

Also Published As

Publication number Publication date
WO1995006717A2 (fr) 1995-03-09
JPH09503656A (ja) 1997-04-15
EP0716691A1 (fr) 1996-06-19
AU7681394A (en) 1995-03-22
WO1995006717A3 (fr) 1995-04-06

Similar Documents

Publication Publication Date Title
Mosca et al. Mesenchymal stem cells as vehicles for gene delivery.
KR101015913B1 (ko) 조혈모세포의 유전적 변이 치료 방법 및 변이 세포의 용도
JPH08510134A (ja) Ｈｉｖ感染およびエイズを対象としたリボザイム遺伝子治療
CN101415827A (zh) 产生抗原特异性效应t细胞的方法
AU2010274031A1 (en) Dual vector for inhibition of human immunodeficiency virus
MXPA04009287A (es) Proceso para producir linfocito citotoxico.
Matis et al. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen.
US20030219463A1 (en) T cell receptor transfer into a candidate effector cell or a precursor thereof
Burt et al. Herpes simplex thymidine kinase gene–transduced donor lymphocyte infusions
AU712415B2 (en) Transplantation of genetically modified cells having low levels of class I MHC proteins on the cell surface
ES2358187T3 (es) Procedimientos para la modificación genética de las células progenitoras hematopoyéticas y utilizaciones de las células modificadas.
JPH06503719A (ja) Ｔ↓ｈ依存性細胞障害性Ｔリンパ球の産生方法
JPH11514209A (ja) 組換えレトロウイルス調製物による造血幹細胞の高効率エクスビボ形質導入
Poznansky et al. Inhibition of human immunodeficiency virus replication and growth advantage of CD4+ T cells and monocytes derived from CD34+ cells transduced with an intracellular antibody directed against human immunodeficiency virus type 1 Tat
CA2158933A1 (fr) Methodes de suppression du rejet de greffes
EP0716710B1 (fr) Procedes de suppression de la reponse immunitaire par therapie genique
CA2158932A1 (fr) Methodes de suppression de la reponse auto-immunitaire
JP2004523202A (ja) 遺伝子修飾ｔ細胞、該細胞の製造方法および該細胞の使用
AU2017254831B2 (en) Dual vector for inhibition of human immunodeficiency virus
Heslop et al. Gene-marking and haemopoietic stem-cell transplantation
AU2004252010A1 (en) Method for transplanting lymphohematopoietic cells into mammal
US20060051866A1 (en) Means of producing and utilising a population of disease specific cytotoxic t-lymphocytes
US6984379B1 (en) Gene therapy by administration of genetically engineered CD34+ cells obtained from cord blood
US20030091546A1 (en) Methods of suppressing immune response by gene therapy
Fesnak et al. Immunotherapy with Autologous Cells

Legal Events

Date Code Title Description
FZDE Dead